Augusto Miravalle, MD
Associate Clinical Professor, Neurology
Medical School
- MD, Universidad Nacional de La Plata (2001)
Internship
- Resurrection Medical Center Program (2005)
Residencies
- Loyola University/Cook County Hospital Program, Neurology (2007)
- Loyola University Program, Chief Resident, Neurology (2008)
Languages
Spanish, EnglishDepartment
NeurologyPublications
- Miravalle A, Corboy J. Therapeutic options in MS. Five new things. Clinical Pratice Journal. Neurology. 2010;75(Suppl 1):S22-S27
- Joseph R. Berger, Giancarlo Comi, Christian Confavreux, Fred Lublin, Augusto Miravalle, et al. Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis. Annals of Neurology. 2010;68:3:409-411
- Miravalle A, Schnitzler E, Bonwit A, Biller J. Neurological complications of vaccinations. Neurological Research. 2010;32:3:285-292.
- Corboy J, Miravalle A. Emerging therapies for the treatment of MS. Journal of Inflammation Research. 2010:3 53-59
- Miravalle A, Jensen R, Kinkel R. Immune reconstitution syndrome after discontinuation of Natalizumab therapy in patients with MS. Archives of Neurology. 2010
- Nilsen S, Miravalle A, Langer Gould A, Cooper J, Kinkel R. B Cell Depletion and Safety of Low Dose Rituximab in Patients with Relapsing Multiple Sclerosis. Submitted for publication 2010.
- Nilsen S, Miravalle A, Langer Gould A, Cooper J, Kinkel R. B Cell Depletion and Safety of Low Dose Rituximab in Patients with Relapsing Multiple Sclerosis. Submitted for publication 2010.
- Kala M, Miravalle A, Vollmer T. Recent advances in mechanism of action of Glatiramer acetate. Submitted for publication. 2010
- Schreiner T, Miravalle A. Current and emerging therapies for Multiple Sclerosis: Focus on Cladribine. Journal of Central Nervous System Disease 2012;41-14
- West MS, Miravalle A. Profile of oral laquinimod and its potential in the treatment of multiple sclerosis. Degenerative Neurological and Neuromuscular disease. 2011:1; 25 - 32
- Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KE, Kinkel RP. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Multiple Sclerosis Journal 9 August 2011
- Miravalle A. Guidelines and Best Practices for Appropriate Use of Dalfampridine in Managed Care Populations. The American Journal of Managed Care. 17:5; May 2011
- Miravalle A, Hendin B, Vollmer T and Kala M. Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 2011:3 151–158
- Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of Glatiramer acetate. J Neuroimmunol. 2011
- Miravalle A, Jensen R, Kinkel R. Immune reconstitution inflammatory syndrome after discontinuation of Natalizumab therapy in patients with MS. Arch Neurol. 2011 Feb;68(2):186-91
- Miravalle AA, Schreiner T. Neurologic complications of vaccinations. Handb Clin Neurol. 2014;121:1549-57. PubMed PMID: 24365435
- Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr;19(4):278-85. PubMed PMID: 23725360
- Roos KL, Miravalle A. Postinfectious Encephalomyelitis. Infections of the Centeral Nervous System. Scheld WM, Whitley RJ, Marra C. Third edition. Lippincott Williams & Wilkins, Philadelphia 2013
- Selmaj K, Zipp, F, Bar-Or A, Miravalle A, Due, B, Vollmer T on behalf of the DreaMS study group. A randomized trial of ONO-4641 in Relapsing-Remitting Multiple Sclerosis. Submitted to New England Journal of Medicine June, 2013.
- Liewluck T, Miravalle A. Immune-Mediated Neurological Disorders. Curr Neurol Neurosci Rep. 2015 Sep;15(9):61. PubMed PMID: 26202897
- Harlow DE, Honce JM, Miravalle AA. Remyelination Therapy in Multiple Sclerosis. Front Neurol. 2015;6:257. PubMed PMID: 26696956
Professional Memberships
- American Academy of Neurology, Member
Specialty Information
Specialties- Neurology, Board Certification (2008)
Clinical Interests
I sub-specialize in Multiple Sclerosis and related neuro-immunological disorders of the brain and spinal cord. I am particularly interested in gray matter pathology, particularly neocortical volume changes, cortical lesions, and their impact on cognitive and physical disability.
I sub-specialize in Multiple Sclerosis and related neuro-immunological disorders of the brain and spinal cord. I am particularly interested in gray matter pathology, particularly neocortical volume changes, cortical lesions, and their impact on cognitive and physical disability.